|
Gert W. Munthe
Chair
|
Gert W. Munthe (born 1957) has been chair of the board since 2004. He is also the managing partner and founder of Herkules
Capital. Mr Munthe has over 20 years of senior executive and CEO experience. Prior to founding Herkules Capital, he was CEO
of Alpharma, Inc, a NYSE-listed pharmaceutical company, from 1998 to 2000, and CEO of NetCom ASA, a leading Norwegian GSM
operator, from 1993 to 1998. Mr Munthe holds a degree in economics from the University of Oslo, and both an MBA and an MIA
from Columbia University in New York. He is a Norwegian citizen.
|
|
Jo Lunder
Board member
|
Jo Lunder (born 1961) has been a board member since 2007. He became president of Ferd Industrial Holdings AS on 1 September
2007, and executive vice president of Ferd Holding AS. He was previously president and CEO of Ementor ASA, which is listed
on Oslo Stock Exchange. From 1999 to 2004, he was chair, CEO and COO of VimpelCom, the leading Russian GSM operator listed
on the New York Stock Exchange. From 1993 to 1999, Mr Lunder held several executive management positions at Telenor Mobil,
including deputy CEO. Before that, he had various senior management positions with Nordea/ Norgeskreditt. Mr Lunder holds
a bachelors degree from Oslo Business School and an MBA from Henley Management College. He completed an executive management
programme at IMD in 1998. Mr Lunder is a Norwegian citizen.
|
|
Siri Fürst
Board member
|
Siri Fürst (born 1958) has been a board member since 2007. She is a partner in Considium Consulting Group AS, and has broad
experience from pharmaceutical activities. This derives from positions as general manager at DiaGenicASA from 2000 to 2003,
and as vice president of strategy and business development at Nycomed Pharma AS from 1997 to 1999 and Hafslund Nycomed AS
from 1995 to 1997. Ms Fürst was also vice president of investor relations for Hafslund Nycomed AS from 1991 to 1994. She currently
holds several directorships, including Aker Kværner ASA, SNN Invest AS and Medinnova AS. Ms Fürst has a degree in economics
from the Norwegian School of Economics and Business Administration. She is a Norwegian citizen.
|
|
Jo Klaveness
Board member
|
Jo Klaveness (born 1954) has been a board member since 2007. He is currently president, CEO and founder of Drug Discovery
Laboratory AS, as well as a professor in medicinal chemistry at the School of Pharmacy of the University of Oslo. From 1983
to 1994, Dr Klaveness served in various positions at Nycomed, including project manager, director and vice president in the
research and development organisation. Dr Klaveness is the inventor of more than 120 patent families related to several pharmaceuticals
currently on the market. He has a PhD and an MSc in organic chemistry and a MSc Pharm in pharmaceutical chemistry, all from
the University of Oslo. Mr Klaveness is a Norwegian citizen.
|
|
Rikke Tobiasson Reinemo
Board member
|
Ms. Rikke Tobiasson Reinemo (born 1975), has been a member of the board since June 2007. She is an investment manager at Herkules
Capital. Prior to this, Ms. Reinemo worked at McKinsey & Company. She graduated with a degree in economics and business economics
from the Norwegian School of Management.
|
|
Hilde Furberg
Board member
|
Hilde Furberg (born 1958) has been a member of the board since May 2011. She has held various positions within Genzyme since
2002, where she currently serves as Senior Vice President PGH (Personalized Genetic Health) Europe. Ms Furberg has long term
experience from various fields within the pharmaceutical sector, including as Managing Director in Baxter. She holds a directorship
also in Copenhagen Capacity. Ms Furberg holds a Master of Science degree from the University of Oslo. She is a Norwegian citizen.
|
|
Sverre Magne Sondbø
Employee representative
|
Sverre Magne Sondbø (born 1959) has been a board member of Pronova BioPharma Norge AS since 1999 and of Pronova BioPharma
ASA from 2007. He has been a process development manager at Pronova BioPharma since 1997. Before joining the group, he was
production manager of Denja, Rieber & Søn from 1993 to 1996. From 1990 to 1993, he worked as a product developer for Ringnes
Breweries, and was a laboratory manager (1985-1987) and later general manager (1987-1990) at the Norwegian Directorate of
Fisheries in Svolvær. Mr Sondbø has an MSc in technical biochemistry from the Norwegian University of Science and Technology.
Mr Sondbø held 9 500 shares in the company at 31 December 2010. He is a Norwegian citizen.
|
|
Martin Jack Mattison
Employee representative
|
Martin Jack Mattison (born 1977) has been a board member of Pronova BioPharma ASA since May 2010. He is currently business
controller for the Kalundborg site. Before joining the group, Mr. Mattison was employed at Novo Nordisk A/S from 2004 – 2008.
He holds a Certificate in Business Administration and expects to complete his Diploma Degree in Financial and Management Accounting
from the University of Southern Denmark in June 2011. Mr. Mattison is a Danish citizen.
|
.
|
Wenche Gordon
Employee representative
|
Wenche Gordon (born 1947) has been a board member of Pronova BioPharma ASA since 2011. She has been regulatory project director
at Pronova BioPharma since 2008, and was director of regulatory affairs in the period 2002-2007. She has previously had positions
in regulatory affairs at GE Healthcare (1988-1997) and Roche (1983-1988), and has had various positions at Dumex (1978-1982).
In addition she has been working in retail and hospital pharmacy for a total period of ten years, and for a short period at
the Norwegian Medicines Agency. Ms. Gordon has an M.Sc.Pharm. degree from the University of Oslo. Ms Gordon held 1 000 shares
in the company at 31 December 2010.
|
|
